Showing 1 - 3 results of 3 for search 'Paola Facheris', query time: 0.01s Refine Results
  1. 1
    Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study

    Long-term effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis with and without cardiometabolic comorbidities: a single-center retrospective study by Luciano Ibba, Sara Di Giulio, Luigi Gargiulo, Paola Facheris, Chiara Perugini, Antonio Costanzo, Alessandra Narcisi, Mario Valenti

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study

    Upadacitinib 30 mg for the optimal management of moderate-to-severe atopic dermatitis: a 52-week single-center real-world study by Luigi Gargiulo, Luciano Ibba, Matteo Bianco, Sara Di Giulio, Alfano Alfano, Ruggero Cascio Ingurgio, Paola Facheris, Chiara Perugini, Mario Valenti, Antonio Costanzo, Alessandra Narcisi

    Published 2024-12-01
    Get full text
    Article
    Save to List
    Saved in:
  3. 3
    The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis

    The nature of the post-translational modifications of the autoantigen LL37 influences the autoreactive T-helper cell phenotype in psoriasis by Roberto Lande, Anna Mennella, Raffaella Palazzo, Rebecca Favaro, Rebecca Favaro, Paola Facheris, Flavia Mancini, Giuseppe Ocone, Elisabetta Botti, Mario Falchi, Immacolata Pietraforte, Curdin Conrad, Luca Bianchi, Antonio Costanzo, Antonio Costanzo, Loredana Frasca

    Published 2025-04-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: